LifeSci Capital Remains a Buy on Eledon Pharmaceuticals (ELDN)

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Eledon Pharmaceuticals (ELDNResearch Report) today and set a price target of $3.45. The company’s shares opened today at $3.57.

According to TipRanks, Katkhuda is an analyst with an average return of -22.5% and a 21.74% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Vera Therapeutics, and Cincor Pharma.

Eledon Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $14.73.

See the top stocks recommended by analysts >>

The company has a one-year high of $4.39 and a one-year low of $2.03. Currently, Eledon Pharmaceuticals has an average volume of 15.59K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Eledon Pharmaceuticals, Inc. (Nasdaq:ELDN) is an immunology-focused biotechnology company utilizing its experience in the CD40/CD40L costimulatory pathway to develop and commercialize precision therapies for persons undergoing organ and cellular transplantation, and for people living with autoimmune and neurodegenerative disease. The company’s lead compound in development is tegoprubart (AT-1501), an anti-CD40L antibody. The company, which was established in 2004, is headquartered in Irvine, CA.

Read More on ELDN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More